Get the Stockscreener App
98.73
1.91%
1.85
Insmed Inc stock is traded at $98.73, with a volume of 5.19M.
It is up +1.91% in the last 24 hours and up +50.25% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$96.88
Open:
$96.46
24h Volume:
5.19M
Relative Volume:
1.88
Market Cap:
$13.41B
Revenue:
$381.03M
Net Income/Loss:
$-1.01B
P/E Ratio:
-16.59
EPS:
-5.95
Net Cash Flow:
$-789.25M
1W Performance:
+34.11%
1M Performance:
+50.25%
6M Performance:
+37.83%
1Y Performance:
+60.20%
1-Day Range:
$96.01
$99.65
1-Week Range:
$70.57
$100.00
52-Week Range:
$60.40
$100.00
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
98.73 | 13.41B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed Inc (INSM) Soars 30% on Impressive Study - MSN
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results - Insider Monkey
INSM September 19th Options Begin Trading - Nasdaq
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - Yahoo Finance
Insmed (INSM) Soars After Raising $650 million - MSN
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
Insmed Inc (INSM). Soars 30% on Impressive Study - Yahoo Finance
SEC Form 424B5 filed by Insmed Incorporated - Quantisnow
Insmed prices capital raise of $750 via stock offering - MSN
Insmed announces $650M public offering of common stock - MSN
Insmed Stock Ends Volatile Session Lower, Pauses After Monumental 32% Weekly Surge - Daily Chhattisgarh News
Insmed aims to raise $750M in one of the largest stock offerings this year - Endpoints News
Stocks To Watch: Insmed Sees RS Rating Jump To 93 - MSN
Insmed (INSM) Secures $750 Million Through Stock Offering - GuruFocus
Insmed is an attractive, but expensive takeout meal - statnews.com
INSM Increases Common Stock Offering to $750M | INSM Stock News - GuruFocus
Insmed Prices $750 Million Common Stock Offering - marketscreener.com
Bank of America Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - Defense World
Insmed Raises Massive $750M in Stock Offering to Advance Breakthrough Drug Pipeline - Stock Titan
INSM: Mizuho Raises Price Target for Insmed to $110 | INSM Stock News - GuruFocus
Insmed Prices Public Offering Of About 7.81 Mln Shares At $96.00/shr - Nasdaq
Insmed raises $750 million in public offering of common stock By Investing.com - Investing.com Canada
Insmed Announces Pricing of $750 Million Public Offering of Comm - GuruFocus
Insmed raises $750 million in public offering of common stock - Investing.com
Insmed Announces Pricing Of $750 Million Public Offering Of Common Stock At $96 Per Share - marketscreener.com
Insmed Announces Pricing of $750 Million Public Offering of Common Stock - marketscreener.com
These 10 Stocks Are Flying High - Insider Monkey
Insmed (INSM) Plans $650M Public Offering of Common Stock | INSM - GuruFocus
Insmed's drug for rare lung disease meets main goal in mid-stage trial - MSN
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM) - Yahoo Finance
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Benzinga
Insmed (INSM) Plans $650M Stock Offering, Shares Fall - GuruFocus
Insmed announces $650 million public offering of common stock - Investing.com
Insmed announces $650 million public offering of common stock By Investing.com - Investing.com Canada
Insmed Plans $650 Million Public Offering - marketscreener.com
Insmed announces $650M common stock offering - TipRanks
Insmed Announces Proposed $650 Million Public Offering of Common Stock | INSM Stock News - GuruFocus
Insmed Announces Proposed $650 Million Public Offering of Common Stock - Yahoo Finance
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Liquidia: Competitor Insmed's Stunning PAH Data Arrives At Precisely The Wrong Time (LQDA) - Seeking Alpha
Insmed (INSM) Stock Surges Over 8% as Phenomenal Rally Continues - Daily Chhattisgarh News
Insmed (INSM) Target Price Raised by Goldman Sachs | INSM Stock News - GuruFocus
Insmed at Goldman Sachs: Strategic Milestones and Financial Strength By Investing.com - Investing.com Nigeria
Insmed at Goldman Sachs: Strategic Milestones and Financial Strength - Investing.com
Transcript : Insmed Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - marketscreener.com
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast - Benzinga
BofA Securities Raises Insmed Price Target to $109 From $94, Maintains Buy Rating - marketscreener.com
Insmed (INSM) Maintains Outperform Rating as Price Target Rises - GuruFocus
Phase III next for buoyant Insmed - The Pharma Letter
Insmed Stock Jumps 29% on Encouraging PAH Study Results - Yahoo Finance
INSM: Morgan Stanley Raises Price Target to $102 and Maintains Overweight Rating | INSM Stock News - GuruFocus
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flammer Martina M.D. | Chief Medical Officer |
Jun 10 '25 |
Option Exercise |
26.46 |
25,740 |
681,080 |
108,851 |
| Flammer Martina M.D. | Chief Medical Officer |
Jun 11 '25 |
Option Exercise |
17.07 |
19,423 |
331,551 |
102,534 |
| Flammer Martina M.D. | Chief Medical Officer |
Jun 10 '25 |
Sale |
88.64 |
25,740 |
2,281,594 |
83,111 |
| Flammer Martina M.D. | Chief Medical Officer |
Jun 11 '25 |
Sale |
94.50 |
19,423 |
1,835,474 |
83,111 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Jun 11 '25 |
Option Exercise |
13.91 |
70,000 |
973,700 |
188,579 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Jun 10 '25 |
Option Exercise |
17.16 |
38,300 |
657,228 |
156,879 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Jun 11 '25 |
Sale |
93.42 |
99,172 |
9,264,345 |
89,407 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Jun 10 '25 |
Sale |
88.64 |
38,300 |
3,394,912 |
118,579 |
| Bonstein Sara | Chief Financial Officer |
Jun 10 '25 |
Option Exercise |
18.02 |
47,890 |
862,884 |
161,178 |
| Bonstein Sara | Chief Financial Officer |
Jun 10 '25 |
Sale |
89.12 |
57,766 |
5,148,024 |
103,412 |
1.17%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):